Strategic Positioning Hassman Research Institute is a mid-sized clinical trial site organization with inpatient and outpatient facilities, specializing in early-phase pharmacology, HAL/HAP studies, psychedelic trials, and neuroimaging capabilities, presenting a differentiated offering for sponsors seeking diverse study modalities.

Integrated Platform As a division of Apex Innovative Sciences with a history of mergers and acquisitions, HRI offers access to a broader sponsor network and consolidated trial-site services, enabling potential cross-sell of site management, coordination, and trial execution capabilities.

Expansion Readiness With 88 inpatient beds and facilities in Marlton and Berlin, NJ, HRI demonstrates scalable infrastructure and capacity for higher enrollment and multi-site studies, making it attractive for sponsors requiring flexible site staffing and patient recruitment.

Diverse Study Expertise Experience spans healthy volunteer studies, early-phase pharmacology, HAL/HAP, driving simulations, and first-in-human trials, offering sponsors a single partner for a wide range of trial types and populations.

Financial Viability Current revenue range signals a financially stable mid-sized CRO-like partner, enabling predictable budgeting for trial onboarding, site fees, and potential growth opportunities through expanded collaborations within Apex’s network.